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The Arab world is one of the largest geo cultural units in the
world with a population exceeding 300 million and spanning more
than 14,000,000 square kilometers, from the Atlantic Ocean in the
west to the Arabian Sea in the east. The Arabs in general are genet-
ically very diverse and united by history dating back to 3500 BC
[1]. In Saudi Arabia, both dramatic recent changes in lifestyle with
subsequent obesity and metabolic syndrome, and possible speciﬁc
genetic predisposition are probably responsible for Type 2 Diabe-
tes (T2D) at epidemic levels. In the early eighties, T2D was not
common in Saudi Arabia [2], and among the male Saudi population
its prevalence was not different from other parts of the world [3].
However, this seems to have changed in the last two decades since
the prevalence of T2D in Saudis is now one of the highest in the
world [4]. Another particularity of Saudi Arabia is a rate of consan-
guinity as high as 57.7%, with ﬁrst cousin marriage being 28.4% fol-
lowed by distant relative marriage at 14.6% [5]. Given this speciﬁc
context, familial aggregation of T2D can yield an odds ratio of 6.2,
suggesting an increased genetic susceptibility to the disease [6].
The limited genetic diversity and reduced allelic heterogeneity
observed in such isolated populations is well known to facilitate
the discovery of loci contributing to both Mendelian and complex
diseases. Genome-wide association studies (GWAS) in the Saudi
population are therefore very promising in identifying novel genet-
ic factors associated with T2D.
2. Strategies, successes and failures of studies in Europeans
Studies of families, populations and twins show that T2D has a
strong genetic component [7–13]. A concordance rate of 0.20–0.91
for T2D was observed in monozygotic twins compared with 0.10–
0.43 in dizygotic twins [11,12]. In the population-based Framing-
ham Offspring Study, the odds ratio for T2D in off springs with
parental diabetes is 3.5 when one parent is affected and 6.1 when
both parents suffer from the disease, compared with individuals
without parental diabetes [8]. Overall, the heritability of T2D was
estimated to range from 30% to 70%, depending on the population
investigated [13].
Early attempts to identify genes associated with T2D were
rather unsuccessful, due to the limited sample size and the approx-
imation of screening methods, such as candidate gene and posi-
tional cloning from family linkage studies. Despite considerable
research throughout the world, only PPARG Pro12Ala [14] and
KCNJ11 E23K [15] variants were unanimously found to predispose
individuals to T2D. Identifying mutations leading to monogenic
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Oof their contribution to T2D pathophysiology [16]. Both genes code
for proteins that are drug targets for T2D. However, other good
candidates such as CAPN10, GCK, HNF1A, HNF4A, ACDC/ADIPOQ/
adiponectin, ENPP1/PC-1, and RETN [17] were identiﬁed, but were
not yet consistently associated with T2D. At that time, the scien-
tiﬁc community considered that the genetic component of T2D
may comprise only variants with modest effects. In 2006, a re-
search group explored a modest linkage peak on chromosome
10q, and identiﬁed intronic polymorphisms in the transcription
factor 7-like 2(TCF7L2) gene, showing a strong association with
T2D in Icelandic, US and Danish samples [18]. Fine-mapping anal-
ysis of this locus led to the conclusion that an increased risk for
T2D was most likely to be associated with the rs7903146 T allele
[19]. This ﬁnding has been replicated in most populations, with
an overall odds ratio of 1.4 per risk allele [17,20]. Such an effect
size was twice as high as that from previous conﬁrmed genes
[20]. In 2007, common risk variants were identiﬁed in candidate
genes, WFS1 and HNF1B (TCF2), involved in autosomal dominant
conditions characterized by the development of T2D [21,22].
In 2005, the completion of the human genome sequence, the
identiﬁcation of human genetic variants and the provision of a
haplotype map (HapMap), together with rapid improvements in
genotyping technology and analysis, have permitted GWAS to be
undertaken in a large number of samples [23]. However, the
increased number of statistical tests performed presented an
unprecedented potential for false-positive results, leading to new
stringency in acceptable levels of statistical signiﬁcance
(5  108 for 1 million tests) and requirements for replication of
ﬁndings [24]. In 2007, the ﬁrst GWAS for T2D was performed by
the Diabetes Gene Discovery Group (DGDG) on the French popula-
tion [25]. This study conﬁrmed that TCF7L2 is the strongest genetic
risk factor for T2D, and identiﬁed two risk polymorphisms in the
SLC30A8 and HHEX genes. Subsequently, four back-to-back studies
conﬁrmed previously reported associations and identiﬁed CDKAL1,
IGF2BP2 and CDKN2A/B as novel loci [26–29].
The FTO variant was also associated with higher odds of T2D,
although this effect can be entirely explained by differences in
body mass index between case and control subjects [30]. FTO is in-
deed a ‘‘pure” obesity gene, probably acting through an effect on
food intake behavior. In order to increase the statistical power of
the GWAS, several studies were then combined in a meta-analysis
that discovers six additional T2D loci (JAZF1, CDC123-CAMK1D,
TSPAN8-LGR5, THADA, ADAMTS9 and NOTCH2ADAM30) [31]. It
should be understood, however, that the gene mapping for T2D
was mostly performed with population samples of European ori-
gin, without capturing the full range of human genetic diversity
[32]. In 2008, the ﬁrst GWAS were ﬁnally conducted in Japanese
cohorts and showed that polymorphisms in the potassium channel
KCNQ1 locus were associated in both Japanese and also to a lesser
extent in European populations [33,34]. In 2008 and 2009, follow-
ing the success of GWAS that used T2D as a categorical trait, wepen access under CC BY-NC-ND license.
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titative glycemic traits [35]. One of these loci is the melatonin
receptor 2 MTNR1B that is associated with increased fasting glu-
cose levels, impaired insulin secretion and T2D risk [36]. As for
T2D, large GWAS meta-analyses on glycemic traits further demon-
strated novel association of ADCY5, PROX1, GCK, GCKR and DGKB-
TMEM195 with T2D [37]. An alternative method was to perform
a multiple-stage study in homogenous populations (rather than
pooling analyses from diverse cohorts), each stage containing a
smaller number of SNPs and a larger number of subjects than
the previous stage, increasing power by focusing on the most sig-
niﬁcant SNPs in each stage [38]. This approach allowed the identi-
ﬁcation of a polymorphism near the gene coding for the insulin
receptor substrate 1, IRS1, associated with insulin resistance and
hyperinsulinemia [39]. Recently, the initial meta-analysis of T2D
was extended to discover 12 novel T2D-association signals, includ-
ing a second independent signal at the KCNQ1 locus, the ﬁrst report
of an X-chromosomal association (near DUSP9), and a further in-
stance of overlap between loci implicated in monogenic and multi
factorial forms of diabetes (HNF1A) [40]. Overall, about 40 genes
have been included so far in the ‘‘black list” of genes associated
with T2D. Most of these genes are expressed in the pancreatic beta
cell (with the exception of IRS1) and are though to primarily
impact insulin secretion.
Although GWAS have given us a deeper insight into the com-
plex genetic architecture of T2D, this approach has some limita-
tions. In fact, the translation of emerging genomic knowledge
into public health and clinical care is one of the major challenges
for the coming decades [41]. An essential prerequisite for person-
alized medicine to become feasible is a predictive test that can dis-
criminate between individuals who will develop T2D and those
who will not. However, the common variants described by GWAS
have modest predictive power, and in combination, explain only a
small fraction of heritability [42]. Many common variants with
small effects or fewer rare variants with stronger effects are still
to be discovered, and may further improve the discriminative
accuracy of predictive genetic testing for T2D [43]. In summary,
the GWAS of frequent SNPs primarily performed in European pop-
ulation have proven useful, but a substantial ‘‘missing heritability”
dark matter is still unknown.
3. From candidate gene to genome-wide studies in Saudis
The Saudi population is still terra incognita for geneticists who
have mostly focused their studies on individuals of European des-
cent, as previously shown. Only three genes of the ‘‘black list” have
been assessed with contrasted results that may be due to true
genetic differences or to power/design issues. In a case-control
association study using 1137 Saudi T2D and 219 controls (age
>60; fasting plasma glucose <7 mmol/L), the PPARG Pro12Ala was
not signiﬁcantly associated with T2D [44]. However, given that
the risk allele frequency is 0.96 in the Saudi population, the
authors acknowledged that study size was extremely underpow-
ered. In a second analysis of 522 Saudi T2D patients (WHO criteria)
and 346 controls (age >60; fasting plasma glucose <7 mmol/L), Al
Samadi and colleagues observed no association between T2D and
TCF7L2 polymorphisms [45], although considered as good quality
controls in most genetic studies. It is now well established that
TCF7L2 polymorphisms are more associated with T2D in non-obese
individuals than in obese subjects [46], but the authors could not
take into account the body mass index in their statistical model
of analysis. In a third case-control study of 550 T2D Saudi patients
and 335 controls (age > or =60; fasting plasma glucose <7 mmol/L),
the KCNJ11 E23K polymorphism was more common among T2D
patients (21%) than in age and sex matched controls (13.6%)
(OR = 1.7, p = 0.0001) [47]. In the three studies mentioned above,the controls were non-diabetic individuals, including glucose intol-
erant subjects who may develop T2D later in life. Given that genet-
ic studies in subjects of European ancestry have taken a great leap
forward in genotyping millions of markers in hundreds of thou-
sands of samples, it is now time to use genome-wide approaches
to analyze the Saudi genome.
In the near future, microarrays will expand coverage of com-
mon and rare genetic variation with 5 million variants per sample,
incorporating an optimized set of SNPs chosen from all three
phases of HapMap and from the 1000 Genomes Project (http://
www.illumina.com). However, these arrays will be designed based
on European, African and Asian DNA sequences. In each new hab-
itat encountered, natural selection has acted to increase the fre-
quency of variants that provided an advantage, and to eliminate
those that were harmful, while the rest of the genome passively
gained and lost genetic variation. The end result is a set of human
populations that, while extremely similar across the genome as a
whole, can carry quite different sets of genetic variants relevant
to disease. In addition, the linkage disequilibrium can also differ
between populations, so that a marker that is tightly correlated
with a disease variant in one population may be only weakly asso-
ciated in other groups. These differences have a profound implica-
tion for disease gene mapping efforts. Therefore, the whole-
genome sequencing of Saudi samples would be a solution, but re-
mains very expansive and time-consuming so far. Alternatively, a
number of studies have shown that using the geographically near-
est reference population, or a combination of adjacent populations
as a reference, usually gives the best results for these populations.
Speciﬁcally, HapMap YRI (Nigeria) and/or CEU (Utah residents with
northern and western European Ancestry) may provide rather
acceptable portability for Middle East populations [48–51].
A large fraction of the genetic risk of T2D will probably be the
result of rare variants having a strong functional effect, and the lat-
est results from GWAS of T2D have failed to provide unambiguous
support for the ‘‘common disease, common variant” hypothesis
[52]. The alternative ‘‘common disease, rare variant” hypothesis
remains to be tested. In a short-term range, the solution will be
higher-density SNP chips, incorporating lower frequency variants
identiﬁed by large-scale sequencing projects like the 1000 Gen-
omes project. However, such approaches will have diminishing re-
turns. As chip makers lower the frequency of the variants on their
chips, the number of probes that will have to be added to capture a
reasonable fraction of the total genetic variation will increase
exponentially, with each new probe adding only a slight increase
in power. Ultimately, the answer lies in large-scale sequencing,
which will provide a complete catalogue of every variant in the
genomes of both T2D patients and controls. As coding regions con-
stitute only 1% of the human genome, yet harbor 85% of the muta-
tions, with a large effect on disease-related traits, exome
sequencing is a potentially cost-efﬁcient strategy for identiﬁcation
of rare functional mutations [53].
Both GWAS and exome sequencing approaches complement
each other. A limitation of genome-wide association studies is
the lack of any functional link between the vast majority of risk
variants and the disorders they putatively inﬂuence. Furthermore,
very few published risk variants lie in coding regions. It has be-
come common practice to describe risk variants derived from
GWAS as ‘‘in” a gene, suggesting that the gene harboring the var-
iant inﬂuences the disorder but ‘‘in” in this context has a purely
physical meaning [54]. The occurrence of multiple functional
mutations among cases would provide both biological evidence
and epidemiological support for the causal role of the gene or path-
way. A powerful strategy for identifying critical mutations is to
trace the coinheritance of potential disease alleles with the illness
in severely affected families. The possibility of analyzing large and
well-phenotyped multi-generational pedigrees with a family his-
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rare variants associated with the disease [55,56]. While it is gener-
ally accepted that association analysis using unrelated individuals
is more powerful than using related individuals, there are several
advantages that family-based designs have to offer [57]: the
robustness of the design to the effects of population stratiﬁcation
or structure; the possibility to perform genotyping quality con-
trols, to test effect of imprinted genes on phenotypes; the determi-
nation whether a particular allele is inherited or de novo; and
combined linkage and association analysis.
Within the next years, the experience of European studies to
identify the genetic variants associated with T2D and the decreas-
ing price of genome-wide approaches will beneﬁt the Saudi popu-
lation. The ﬁndings generated by genome-wide studies in Saudis
are promising, since genetic risk factors may be shared across dif-
ferent populations, and because novel speciﬁc polymorphisms,
rare variants and etiological pathways may be discovered.
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